UBS Group set a €87.00 ($101.16) price objective on Sanofi (EPA:SAN) in a report issued on Wednesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

SAN has been the topic of several other reports. Jefferies Financial Group set a €90.00 ($104.65) price target on shares of Sanofi and gave the company a buy rating in a report on Friday, June 21st. Credit Suisse Group set a €82.00 ($95.35) price target on shares of Sanofi and gave the company a buy rating in a report on Tuesday, July 30th. Goldman Sachs Group set a €81.00 ($94.19) price target on shares of Sanofi and gave the company a neutral rating in a report on Monday, August 5th. Oddo Bhf set a €94.00 ($109.30) price target on shares of Sanofi and gave the company a buy rating in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. set a €81.00 ($94.19) price target on shares of Sanofi and gave the company a neutral rating in a report on Tuesday, July 30th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of Buy and a consensus price target of €86.29 ($100.33).

Shares of Sanofi stock traded down €0.26 ($0.30) on Wednesday, hitting €75.17 ($87.41). 1,470,246 shares of the company traded hands, compared to its average volume of 3,050,000. The stock’s 50-day moving average is €75.27. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: Investing in Growth Stocks

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.